Document is current
Any future updates will be listed below
-
Authors
Morse, Anne Marie https://orcid.org/0000-0003-4494-0195
Bogan, Richard K. https://orcid.org/0000-0001-7043-2974
Roy, Asim
Thorpy, Michael J. https://orcid.org/0000-0002-3993-2230
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 18 March 2024
First Online: 25 April 2024
Declarations
:
: Anne Marie Morse has received research/grant support and consultancy fees from Jazz Pharmaceuticals, Harmony Biosciences, Avadel Pharmaceuticals, Takeda Pharmaceuticals, Eisai, Alkermes, National Institutes of Health, and Geisinger Health Plan. She is the CEO and founder of DAMM Good Sleep, LLC. Richard K. Bogan is a shareholder of WaterMark Medical and Healthy Humming LLC. He serves on the board of directors for WaterMark Medical. He has served as a consultant to Jazz Pharmaceuticals, Harmony Biosciences, Takeda, Avadel, and Oventus. He has participated in industry-funded research for Avadel, BresoTec, Idorsia, Suven, Jazz Pharmaceuticals, Balance, Vanda, Merck, Eisai, Phillips, Fresca, Takeda, Liva Nova, Roche, Sommetrics, NLS, Sanofi, and Apinemed. He has taken part in speakers bureaus for Jazz Pharmaceuticals, Eisai, Harmony, and Idorsia. Asim Roy has received consultancy fees from Takeda, Avadel, and Inspire. He has participated in industry-sponsored research for Jazz Pharmaceuticals, Harmony, NLS, Eisai, Fisher Paykel, Inspire, Nyxoah, Signifier. Michael J. Thorpy has received fees for serving as a consultant or on advisory boards for Axsome, Balance Therapeutics, Flamel/Avadel, Harmony Biosciences, LLC, Jazz Pharmaceuticals, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, NLS Pharmaceuticals, XW Pharma, Idorsia Pharmaceuticals, and Eisai Pharmaceuticals.
: This article is based on a modified Delphi approach in which all participants originally consented to participate and author the present manuscript. As acknowledged, Phyllis C. Zee, MD, PhD contributed to the consensus panel meetings and participated in the initial drafts of the manuscript. As a result of institutional regulations at a new position, she terminated her participation as an author prior to submission, but provided consent for publication and acknowledgement of her contributions. At the time of her participation, she had served on scientific advisory boards for Jazz Pharmaceuticals plc, Eisai, and Harmony Biosciences; was a consultant for CVS Caremark; and owned stock in Teva.
